Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.
about
Atrial fibrillation: effects beyond the atrium?EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.Redox regulation, NF-kappaB, and atrial fibrillation.LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial)Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase.Fibrosis in Atrial Fibrillation - Role of Reactive Species and MPO.Effects of Angiotensin-II Receptor Blocker on Inhibition of Thrombogenicity in a Canine Atrial Fibrillation Model.Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles.Cross-talk between macrophages and atrial myocytes in atrial fibrillationMechanisms with clinical implications for atrial fibrillation-associated remodeling: cathepsin K expression, regulation, and therapeutic target and biomarker.Physiologic and pathophysiologic role of calpain: implications for the occurrence of atrial fibrillation.Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation.Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation.Microarray analysis in cardiac arrhythmias: a new perspective?ROS signalling between endothelial cells and cardiac cells.Epicardial adipose tissue and atrial fibrillation.Alterations in atrial perfusion during atrial fibrillation.Novel therapeutic targets in the management of atrial fibrillation.Inflammation and the pathogenesis of atrial fibrillation.Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men.Atrial metabolism and tissue perfusion as determinants of electrical and structural remodelling in atrial fibrillation.Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation.Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis.Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia.Atrial thrombogenesis in atrial fibrillation : Results from atrial fibrillation models and AF-patients.Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.
P2860
Q26864877-E100536B-1CDD-4E80-B0FD-52F84044F0BCQ30375302-6F51E7FE-0D4F-4C00-B7CC-A202261CC8D3Q33644314-0B5D6BCE-93DE-46E1-A1AC-D7F9B1C7EA4AQ34223524-F2E86AC1-4424-4504-BB3A-8AE1E6930C79Q34500520-3D159978-4C0A-4808-B8A5-55525EE2B942Q34651371-79213D9C-E965-4663-83A0-CB9D2DAD2A12Q36047754-D2034534-DE62-4964-9341-6241D9395EDCQ36964621-26FC1CAE-BC84-47C4-9E22-29A40486C7C5Q37208100-D1D81B6F-D726-421C-9554-8DD72117C442Q37277429-5DEA66A7-26CD-440D-B85C-7C78FBAED479Q37457719-A6804BFA-7B95-4E7E-8519-9160B1A974D8Q37812402-5BD6F5E7-C24C-4C59-ACD3-66B33FB3A6CEQ37846370-C3765D67-E7DE-4F0E-86CD-1C9D67165F26Q37975121-8D1C5892-B25D-4715-AE42-633D4C50A7CFQ38025390-13798940-C30F-4265-99C5-6D34E68F33C3Q38101386-53848FC6-29B8-4F15-826E-5A77FF3A5A32Q38193013-0EB07655-0890-41B0-BDF7-1C30494EB9DBQ38197585-C77AD337-8074-4099-B243-8EA08A3C2874Q38234147-92522206-1D2A-4FDC-B9C9-B16B348F2CBBQ38236746-7B4EDC2E-8038-4CD3-BC13-AE954A5AE0BFQ38333088-7F8D187A-0782-446C-951F-311B9D4208F9Q38702801-C7B22B62-6473-4606-AC72-EBF52496660AQ38703115-09BC8A8C-4EE5-4AD7-9258-9555A974680FQ38738095-3EBF7711-C99E-4065-9C3F-4E7B10AEBE74Q39439506-B24105AB-EAA2-4C51-8E67-481941C5EDB1Q44814454-2989C3E6-0CC7-4912-B48D-D17DCEA0D897Q46674562-E339ED9C-D4FF-40B8-9068-F81D44C94EEBQ49874468-4AEEE3E7-C4A3-4317-8422-26C1F389BBE2Q53235988-9CC12029-B14D-4334-A747-2BE49AE75F97Q55208569-486F8D2E-9ADC-443E-AFE3-7687D003D656Q55638585-91523055-F410-44FB-A6DF-49E052071CC7
P2860
Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Angiotensin II receptor blocka ...... adhesion molecule expression.
@en
Angiotensin II receptor blocka ...... adhesion molecule expression.
@nl
type
label
Angiotensin II receptor blocka ...... adhesion molecule expression.
@en
Angiotensin II receptor blocka ...... adhesion molecule expression.
@nl
prefLabel
Angiotensin II receptor blocka ...... adhesion molecule expression.
@en
Angiotensin II receptor blocka ...... adhesion molecule expression.
@nl
P2093
P1433
P1476
Angiotensin II receptor blocka ...... adhesion molecule expression.
@en
P2093
Alicja Bukowska
Andreas Goette
Christof Huth
Denis Strugala
Friedrich-Wilhelm Röhl
Helmut U Klein
Jan Pfeiffenberger
Matthias Hammwöhner
Matthias P A Ebert
Michaela Erxleben
P304
P356
10.1161/CIRCULATIONAHA.107.730101
P407
P577
2008-01-28T00:00:00Z